619 results on '"DRUG development"'
Search Results
2. AI-powered clinical trials and the imperative for regulatory transparency and accountability
3. Qualitative Analysis of Inquiries Received by FDA Regarding Conduct of Clinical Trials during the Covid-19 Public Health Emergency
4. Standalone Regulatory Agreements for Product-Development Collaborations in the Medical Products Industry
5. Simultaneous Global Drug Development and Multiregional Clinical Trials (MRCT): 5 Years After Implementation of ICH E17 Guidelines
6. ECLIM-SEHOP: how to develop a platform to conduct academic trials for childhood cancer
7. Insights into Early Interactions on Innovative Developments with European Regulators
8. Microphysiological systems for realizing microenvironment that mimics human physiology—functional material and its standardization applied to microfluidics
9. Polygonum ciliinerve (Nakai) Ohwi: a review of its botany, traditional uses, phytochemistry, pharmacology, pharmacokinetics and toxicology
10. Advancing Transthyretin Amyloidosis Drug Development in an Evolving Treatment Landscape: Amyloidosis Forum Meeting Proceedings
11. Responding to the Call to Action: Framework to Accelerate Clinical Data Generation for Antiretroviral Use in Pregnant Individuals with HIV
12. Digital Health Technology (DHT) in European Clinical Trials, How to Improve the Status-Quo of the Regulatory Landscape?
13. Different Development Strategies Affecting Japan’s Drug lag between Japan-Based and Foreign-Based Companies
14. Recent Advances of Bioactive Marine Natural Products in Drug Discovery
15. Evaluation of ChatGPT and Gemini large language models for pharmacometrics with NONMEM
16. Therapeutic potential of Lawsonia inermis Linn: a comprehensive overview
17. Rational Design of Drugs Targeting G-Protein-Coupled Receptors: Ligand Search and Screening
18. Mechanistic insight and structure activity relationship of isatin-based derivatives in development of anti-breast cancer agents
19. Oral PCSK9 Inhibitors
20. The Role of Genetics in Advancing Cardiometabolic Drug Development
21. A Modified Delphi Study to Establish Essential Clinical Pharmacology Competencies
22. Rational Design of Drugs Targeting G-Protein-Coupled Receptors: A Structural Biology Perspective
23. Evaluation of prompt engineering strategies for pharmacokinetic data analysis with the ChatGPT large language model
24. Many are called, few are chosen: the role of science in drug development decisions
25. Paving the way towards medicines for women and men
26. The microglial P2Y6 receptor as a therapeutic target for neurodegenerative diseases
27. Updates in Alzheimer's disease: from basic research to diagnosis and therapies
28. Phase 0 trials/ Intra-Target-Microdosing (ITM) and the lung: a review
29. In silico molecular screening of bioactive natural compounds of rosemary essential oil and extracts for pharmacological potentials against rhinoviruses
30. Evaluation of the landscape of pharmacodynamic biomarkers in Niemann-Pick Disease Type C (NPC)
31. G protein-coupled receptors and traditional Chinese medicine: new thinks for the development of traditional Chinese medicine
32. Defining the next generation of severe malaria treatment: a target product profile
33. Investigating novel antifungal strategies through molecular docking & dynamics simulations of oxidative stress response in Candida albicans
34. Protein target similarity is positive predictor of in vitro antipathogenic activity: a drug repurposing strategy for Plasmodium falciparum
35. Ebselen analogues delay disease onset and its course in fALS by on-target SOD-1 engagement
36. Leveraging malaria vaccines and mRNA technology to tackle the global inequity in pharmaceutical research and production towards disease elimination
37. Influence of artificial intelligence in modern pharmaceutical formulation and drug development
38. Insight into antioxidant-like activity and computational exploration of identified bioactive compounds in Talinum triangulare (Jacq.) aqueous extract as potential cholinesterase inhibitors
39. Caregiver perspectives on patient-focused drug development for Phelan-McDermid syndrome
40. Analysis of the first ten years of FDA’s rare pediatric disease priority review voucher program: designations, diseases, and drug development
41. Assessing the Role of Patient Generation Techniques in Virtual Clinical Trial Outcomes
42. Anti-Amyloid Therapies for Alzheimer’s Disease: An Alzheimer Europe Position Paper and Call to Action
43. US FDA’s Dose Optimization Postmarketing Requirements and Commitments of Oncology Approvals and the Impact on Product Labels from 2010 to 2022: An Emerging Landscape from Traditional to Novel Therapies
44. Detection, Monitoring, and Mitigation of Drug-Induced Nephrotoxicity: A Pragmatic Approach
45. Development of PI3Kγ selective inhibitors: the strategies and application
46. WANTED DEAD OR ALIVE: New Thinking to Incentivize Drug Development
47. Dissecting the low morbidity and mortality during the COVID-19 pandemic in Africa: a critical review of the facts and fallacies
48. Diagnosing the declining industry sponsorship in clinical research
49. Decisions on Non-oncology Breakthrough Therapy Designation Requests in 2017–2019
50. Non-toxicity of Plant Candicidal Peptides for Mammalian Cell Lines and Galleria mellonella Model to Improving Selectivity for Clinical Use
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.